PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology

PROCLAIM Phase III Study

Everett E. Vokes; Suresh Senan; Joseph A. Treat; Neill A. Iscoe

Disclosures

Clin Lung Cancer. 2009;10(3):193-198. 

In This Article

Objectives

The primary objective of this study is to compare the OS of patients with locally advanced NSCLC of other than predominantly squamous histology when treated with pemetrexed and cisplatin given concurrently with radiation followed by consolidation pemetrexed, compared with a contemporary standard of etoposide cisplatin given concurrently with radiation followed by consolidation therapy with a platinum doublet regimen. Secondary objectives include progression-free survival, sites of first relapse, response rates, survival rates at 1, 2, and 3 years, patient-reported outcomes, toxicity, and laboratory correlates of efficacy and toxicity.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....